Fig. 4: In vivo analgesic profile of the cannabinoid agonists in acute thermal assays.
From: Virtual library docking for cannabinoid-1 receptor agonists with reduced side effects
a Tail flick for CP-55,940 (n = 5 except baseline n = 10; one-way ANOVA, F(5, 29) = 10.9, P < 0.0001), and ‘1350 (n = 5 except baseline n = 10; one-way ANOVA, F(5, 29) = 48.1, P < 0.0001). Asterisks define individual group differences to respective vehicle control after Dunnett’s multiple comparisons post hoc test correction; ‘1350 vehicle vs. baseline: P > 0.99; vehicle vs. ‘1350, 0.05 mg/kg: P = 0.09; 0.1 mg/kg: P = 0.0005; 0.2 and 0.5 mg/kg: P < 0.0001; CP-55,940 vehicle vs. baseline: P = 0.80; vehicle vs. CP-55,940, 0.05 mg/kg: P = 0.91, 0.1 mg/kg: P > 0.99; 0.2 mg/kg: P = 0.32; 0.5 mg/kg: P = 0.0001. b Hot Plate for CP-55,940 (n = 5 except baseline n = 10; one-way ANOVA, F(2, 17) = 148.6, P < 0.0001), ‘1350 (n = 10 except 0.2 and 0.5 mg/kg n = 5; one-way ANOVA, F(4, 35) = 20.7, P < 0.0001), and ‘4936 (n = 10 except 0.05 mg/kg n = 5; one-way ANOVA, F(4, 40) = 6.5, P = 0.0004). Asterisks define individual group differences to baseline or vehicle after Dunnett’s multiple comparisons post-hoc correction; vehicle vs. ‘1350, 0.05 mg/kg: P = 0.85; 0.1 mg/kg: P = 0.006; 0.2 mg/kg: P = 0.0004; 0.5 mg/kg: P < 0.0001; baseline vs. CP-55,940, 0.2 mg.kg: P = 0.2; 0.5 mg.kg: P < 0.0001; vehicle vs. ‘4936, 0.05 mg/kg: P > 0.99, 0.1 mg/kg: P = 0.05, 0.2 mg/kg: P = 0.07; 0.5 mg/kg: P = 0.0002. Data in a & b represent mean ± SEM. For all panels, n denotes number of independent animals per group. ns = not significant, *P < 0.05, **P < 0.01, ****P < 0.001.
